Shampoo for treating less hair and alopecia

A shampoo and hair loss technology, applied in the field of medicine or cosmetics, can solve the problems of insufficient types of medicines and insufficient types of 5α reductase inhibitors, and achieve good application value and the effect of promoting hair growth

Pending Publication Date: 2021-10-15
宜春希宇生物制品有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] But at present, there are not enough types of inhibitors for 5α reductase, and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Shampoo for treating less hair and alopecia
  • Shampoo for treating less hair and alopecia
  • Shampoo for treating less hair and alopecia

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0038] Example 1 II 5α reductase high immunogen screen

[0039] Bioinformatics analysis according to the amino acid sequence of human and mouse type II 5α reductase, combined analysis of secondary structures, antigenicity, affectionate, accessibility and flexibility of PCT protein, and analyzed each segment, selected Highly high zones as a B cell epitope region. Specifically, using Chou & Fasman predicts beta angles, Emini method predicts antigen surface accessibility, Karplus & Schulz predicts protein flexibility, Kolaskar & Tongaonk antigenic analysis, PARKER method protein hydrophobic analysis and technical parameters such as BEPIPRED linear antigen epitope prediction, II type 5α reductase epitope peptide; chemically synthesized epitope peptide segment is: N-CVSGANFLGEIEW-C (SEQ ID NO: 1), the epitope peptide chemical synthesis introduces cysteine ​​in its N-terminal C to improve its cross-linking capabilities with BSA, followed by crosslinking with the BSA. The crosslink rate ...

Example Embodiment

[0040] Example 2I- type 5α reductase monoclonal antibody

[0041] The immunized immunogen synthesized by Example 1 was first immunized with 0.01 M pH 7.4, and Emulsified mixed with Furtic complete adjuvant, 50 μg of immunogen per mouse. Injection of inoculation with the back subcutaneous mouse abdomen. Every 2 to 3 weeks, with the same immunization of the immunization, the immunization of the immunization, 4 times of immunization, 4 times, 1 week after the last immunization, blood, centrifugation, serum, adopt Indirect ELISA method, with an immunogenic package by the enzyme board, detect immunoassays. Mice were screened in immunized titers, with 100 μg immunogen intraperitoneal injection in the last immunization, impact immunity, three days after impact immunization, conventional cell fusion.

[0042] Cell fusion: The first 2D was brought to RPMI-1640. The first 1D was cultured with HAT culture; for the 3rd day after superior immunity for fusion, the blood was collected, and the s...

Example Embodiment

[0045] Example 3 antibody identification

[0046] (1) affinity identification

[0047] The antibody affinity refers to the tightness of the antibody and antigen determination clusters, the stronger affinity is strong, the brighter combination is one of the most important indicators for evaluating the properties of antibody. The affinity of antibodies was determined by kinetic methods using PALL's FORTEBIOCTK2 instruments. As a result, the affinity of the antibody is 7.2 × 10-10, and has a good affinity effect.

[0048] (2) Single anti-specific detection

[0049] A single-resistance detection was used in an ELISA indirect measurement, in an immunogenic peptide as a positive control, the specificity of monoclonal antibody was identified by 2 μg / ml of BSA, II 5α reductase, I-type 5α reductase. Such as figure 1 Indicated.

[0050] From figure 1 As a result, it can be seen that the monoclonal antibody prepared by the present invention has better binding specificity, and can specifica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides the shampoo for treating less hair and alopecia, the shampoo contains the monoclonal antibody specifically aiming at 5 alpha reductase and hesperidin, and experiments prove that the shampoo can well promote mouse hair hyperplasia and has a relatively good application value.

Description

technical field [0001] The invention relates to the field of medicine or cosmetics, and more specifically, to a shampoo for treating hair loss and hair loss. Background technique [0002] Alopecia accounts for more and more in clinical proportion, and the form is various. The etiology of hair loss mainly includes androgenetic alopecia and alopecia areata. The hair follicles of patients with androgenetic alopecia are inherently sensitive to androgen, and the metabolism of 5α-dihydrotestosterone can be inhibited due to the accumulation of 5α-dihydrotestosterone in the hair follicles. Alopecia areata is also considered to be related to immune disorders in addition to nervous system disorders, and is an organ-specific disease mediated by inflammatory cells. The treatment of hair loss includes systemic and local treatments. Oral finasteride and external application of minoxidil tincture have achieved definite curative effects, and high-concentration corticosteroids also have de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K31/7048A61K9/08A61K47/10A61K9/06A61K47/60A61K47/69A61P17/14A61K8/64A61K8/60A61K8/86A61K8/14A61K8/02A61Q7/00
CPCA61K39/3955A61K31/7048A61K9/08A61K47/10A61K9/06A61K9/0014A61K47/60A61K47/6913A61P17/14A61K8/64A61K8/602A61K8/86A61K8/14A61K8/0216A61Q7/00A61K2800/782A61K2800/82A61K2300/00
Inventor 余兵生杨洋
Owner 宜春希宇生物制品有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap